{
  "id": "fda_guidance_chunk_0406",
  "title": "Introduction - Part 406",
  "text": "risks to an individual if they enroll or continue to receive study treatment in a clinical trial after receiving (or having received) the excluded product or the potential impact of the use of the excluded product on trial objectives, such as confounding the determination of effectiveness of the product under investigation. 65 When final, this guidance will represent FDA’s current thinking on this topic. 66 See 21 CFR 312.53(c)(1)(vii) and 312.66. See also the guidance for clinical investigators, sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection (January 2009). Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Oncology Center of Excellence (OCE) May 2023 Biostatistics Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: druginfo@fda.hhs.gov https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs and/or Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 Email: ocod@fda.hhs.gov https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Oncology Center of Excellence (OCE) May 2023 Biostatistics Contains Nonbinding Recommendations i TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND ............................................................................................................... 2 III. RECOMMENDATIONS FOR COVARIATE ADJUSTMENT IN CLINICAL TRIALS .............................................................................................................................. 3 A. General Considerations ................................................................................................................. 3 B. Linear Models ................................................................................................................................ 4 C. Nonlinear Models ........................................................................................................................... 5 IV. REFERENCES .................................................................................................................. 8 Contains Nonbinding Recommendations Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Guidance for Industry1 This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 544320,
  "end_pos": 545856,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.708Z"
}